Vitamins, gut for insulin sensitivity
Coverage this week spotlights vitamins and gut‑health strategies as meaningful levers to improve insulin sensitivity — framed as complements to diet, exercise and weight management (dnpindia.in). The pieces position microbiome and targeted supplementation as adjunctive, not standalone, therapies for reversing insulin resistance (dnpindia.in).
The Instagram clip that sparked the pickups was posted by Nidhi Kakkar, a menopause and women’s wellness coach; NDTV reported her video on Jan. 25, 2026 and the DNP write‑up ran April 1, 2026. (ndtv.com) Clinical research on thiamine (vitamin B1) is mixed: preclinical and small pilot studies suggest metabolic roles, but a BMJ Open review of six randomized trials (364 participants) found no significant effect of thiamine/benfotiamine on HbA1c, fasting glucose or HOMA‑IR. (mdpi.com) Trials of benfotiamine, a lipophilic thiamine derivative, have focused more on reducing advanced glycation end products and vascular or neuropathy endpoints than on core insulin sensitivity; several benfotiamine RCTs and AGE‑focused studies are registered or published. (diabetesresearchclinicalpractice.com) Microbiome interventions show early promise: a 2019 proof‑of‑concept randomized trial of pasteurized Akkermansia muciniphila in overweight, insulin‑resistant volunteers (32 completers) reported improved insulin sensitivity and lower cholesterol after three months. (scispace.com) Larger meta‑analyses of probiotics and synbiotics report modest improvements in fasting glucose, fasting insulin, HbA1c and HOMA‑IR in people with prediabetes and type 2 diabetes, but effect sizes vary by strain, dose and trial duration. (link.springer.com) Experts and recent reviews warn that human evidence is heterogeneous and often small‑scale: strain‑specific responses, host genetics, and short follow‑ups mean next steps are larger, multi‑center RCTs such as the ongoing phase‑2 pAkk trial (planned n=144) and longer benfotiamine trials. (nature.com)
